Skip to main content
Top

Current Treatment Options in Oncology

Issue 1/2024

Content (8 Articles)

Antibody-Drug Conjugates in Gynecologic Cancers

Mary Katherine Anastasio, Stephanie Shuey, Brittany A. Davidson

Sentinel Lymph Node Evaluation in Early-Stage Vulvar Cancer

Courtney A. Penn, Mali K. Schneiter, Catherine H. Watson

Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer

Andrew M. Fang, Jamaal Jackson, Justin R. Gregg, Lisly Chery, Chad Tang, Devaki Shilpa Surasi, Bilal A. Siddiqui, Soroush Rais-Bahrami, Tharakeswara Bathala, Brian F. Chapin

Therapeutic Management of Malignant Wounds: An Update

Adelina-Gabriela Niculescu, Mihaela Georgescu, Ioana Cristina Marinas, Cem Bulent Ustundag, Gloria Bertesteanu, Mariana Pinteală, Stelian Sergiu Maier, Cristina Maria Al-Matarneh, Marian Angheloiu, Mariana Carmen Chifiriuc

Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma

Margaret Wheless, Rajiv Agarwal, Laura Goff, Natalie Lockney, Chandrasekhar Padmanabhan, Thatcher Heumann

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine